← All stocks

CRESCENT BIOPHARMA, INC.

CBIO Net buying
CIK 0001253689 #2943 in the set updated 21 Sep 2026
Bought (120 mo)
$46.91M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$16.73M
$1.51M on a plan · $1.36M straight out of an exercise
Sold at will
$13.86M
34 of 60 sales
Net
+$30.18M
+$33.05M against sales at will

By person

29 insiders · 107 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Fairmount Funds Management LLC entity
Director
$30.61M (2)
+$30.61M
3,601,316
$60.18M
+159.5%
SANDELL SCOTT D
10% owner
$13.04M (14)
−$13.04M
11,326,237
$189.26M
−24.2%
BVF PARTNERS L P/IL entity
10% owner
$11.17M (9)
+$11.17M
62,383
$1.04M
Invus Public Equities, L.P.
10% owner
$3.95M (8)
$488.75K (9)
+$3.46M
6,317,565
$105.57M
−3.7%
Brumm Joshua T
Chief Executive Officer
$920.84K (3) scheduled
−$920.84K
271,765
$4.54M
+1.3%
Rock Edwin
Chief Medical Officer
$725.58K (7)
+$725.58K
680,403
$11.37M
McNeill Jonathan
President and COO
$446.91K (3) scheduled
−$446.91K
134,588
$2.25M
+0.3%
Hahn Brian M.
SVP Finance, CFO
$25.53K (2)
$359.38K (3) scheduled
−$333.84K
70,643
$1.18M
+401.5%
King Rachel K.
Director
$329.13K (1) scheduled
−$329.13K
690,336
$11.54M
+88.4%
Magnani John L.
SVP of Research, CSO
$52.70K (1)
$353.73K (4)
−$301.03K
370,923
$6.20M
+289.5%
JUNIUS DANIEL M
Director
$214.05K (5)
+$214.05K
98,459
$1.65M
BARRETT M JAMES
Director
$169.89K (2) scheduled
−$169.89K
9,089,041
$151.88M
+5.9%
BARRIS PETER J
10% owner
$169.89K (2) scheduled
−$169.89K
9,089,041
$151.88M
+5.9%
NEW ENTERPRISE ASSOCIATES 10 L P entity
10% owner
$169.89K (2) scheduled
−$169.89K
4,995,664
$83.48M
+11.2%
Thackray Helen M.
SVP Clinical Development, CMO
$139.44K (6)
−$139.44K
183,115
$3.06M
+14.0%
Andrews Patricia S
Director
$82.00K (1)
+$82.00K
58,608
$979.34K
Pinkas Jan
Chief Scientific Officer
$34.95K (2) scheduled
−$34.95K
21,581
$360.62K
+2,016%
Im Ellie Eunkyung
Chief Medical Officer
$33.08K (2) scheduled
−$33.08K
21,446
$358.36K
+977.7%
Bispham Barbara Harlin
See Remarks
$33.01K (2) scheduled
−$33.01K
18,710
$312.64K
+780.1%
Semerjian Harout
Chief Executive Officer
$32.25K (1)
+$32.25K
25,000
$417.75K
Scalzo Richard William
Chief Financial Officer
$30.17K (2) scheduled
−$30.17K
19,730
$329.69K
+892.5%
PEARSON TIMOTHY R
Director
$25.03K (1)
+$25.03K
24,650
$411.90K
Johnson Bruce S
SVP & Chief Commercial Officer
$21.20K (1)
+$21.20K
138,980
$2.32M
+10.8%
Lynch Ryan
See Remarks
$12.66K (2) scheduled
−$12.66K
13,631
$227.77K
+596.2%
Girard Armand
SVP, Chief Business Officer
$6.83K (1)
$2.55K (1)
+$4.28K
29,161
$487.28K
Doughty Christopher Grant
Chief Business Officer
62,194
$1.04M
+57.5%
Koenig Scott
Director
36,750
$614.09K
Goldberg Mark Alan
Director
36,325
$606.99K
+216.0%
Jackson Scott Thomas
Director
5,250
$87.73K

No percentages here. This company's share count has moved by a factor of 4.6 over the window, from 13,892,516 to 64,532,091 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
McNeill Jonathan
18 Sep 2026
President and COO
Sold on a plan
3,839
$16.71
$64.15K
Brumm Joshua T
18 Sep 2026
Chief Executive Officer
Sold on a plan
7,837
$16.71
$130.96K
McNeill Jonathan
16 Sep 2026
President and COO
Sold on a plan
731
$17.90
$13.08K
Brumm Joshua T
16 Sep 2026
Chief Executive Officer
Sold on a plan
1,610
$17.90
$28.82K
Bispham Barbara Harlin
16 Sep 2026
See Remarks
Sold on a plan
620
$17.90
$11.10K
Scalzo Richard William
16 Sep 2026
Chief Financial Officer
Sold on a plan
568
$17.90
$10.17K
Im Ellie Eunkyung
16 Sep 2026
Chief Medical Officer
Sold on a plan
623
$17.90
$11.15K
Pinkas Jan
16 Sep 2026
Chief Scientific Officer
Sold on a plan
658
$17.90
$11.78K
Lynch Ryan
16 Sep 2026
See Remarks
Sold on a plan
240
$17.90
$4.30K
Brumm Joshua T
22 Jun 2026
Chief Executive Officer
Sold on a plan
42,305
$17.99
$761.07K
McNeill Jonathan
22 Jun 2026
President and COO
Sold on a plan
20,549
$17.99
$369.68K
Im Ellie Eunkyung
22 Jun 2026
Chief Medical Officer
Sold on a plan
1,219
$17.99
$21.93K
Bispham Barbara Harlin
22 Jun 2026
See Remarks
Sold on a plan
1,218
$17.99
$21.91K
Scalzo Richard William
22 Jun 2026
Chief Financial Officer
Sold on a plan
1,112
$17.99
$20.00K
Pinkas Jan
22 Jun 2026
Chief Scientific Officer
Sold on a plan
1,288
$17.99
$23.17K
Lynch Ryan
22 Jun 2026
See Remarks
Sold on a plan
465
$17.99
$8.37K

What was left out

Form 4 filings counted 191
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 17
Sales on a Rule 10b5-1 plan 16
Sales straight out of an exercise 10
Sales at will 34
Transactions with no price 0
Shares from compensation/vesting 4,400,797
Sales filed before the plan box existed 24
History held since 4 Oct 2016